Data Sheet (Cat.No.TMAY-00235)

Anti-PD-L1 Antibody (9Z343)

Product Details

Ig Type:	Mouse IgG1
Reactivity:	Human
Conjugation:	Unconjugated
Clone:	9Z343
Purification:	Protein A

Applications

Verified Activity:	1. Anti-PD-L1 mouse monoclonal antibody at 1:500 dilution. -Lane A: K562 Whole Cell Lysate. -Lane B: THP1 Whole Cell Lysate. -Lane C: Raji Whole Cell lysate. -Lysates/proteins at 30 µg per lane. -Secondary -Goat Anti-Mouse IgG (H+L)/HRP at 1/10000 dilution. -Developed using the ECL technique. -Performed under reducing conditions. -Predicted band size:33 kDa. -Observed band size:45 kDa. 2. B7-H1 was immunoprecipitated using: -Lane A:0.5 mg K562 Whole Cell Lysate. -4µL anti-B7-H1 mouse monoclonal antibody and 60 µg of Immunomagnetic beads Protein A/G. -Primary antibody: -Anti-B7-H1 mouse monoclonal antibody, at 1:100 dilution. -Secondary antibody: -Clean-Blot IP Detection Reagent (HRP) at 1:1000 dilution. -Developed using the ECL technique. -Performed under reducing conditions. -Predicted band size: 33 kDa. -Observed band size:45 kDa
Application:	WB
Recommended	WB: 1:500-1:2000

Properties

Stability & Storage:	Store at 2°C-8°C for 1 month. Store at -20°C or -80°C for 12 months. Avoid repeated freeze-thaw cycles. Preservative-Free.
Shipping:	Shipping with blue ice.

Antigen Details

Immunogen:	Recombinant Protein: Human PD-L1/B7-H1/CD274 Protein (TMPY-04343)
Antigen Species:	Human
Synonyms:	A530045L16Rik;Pdcd1lg1;Pdcd1l1;Pdl1;CD274 molecule;B7h1
Biology Area:	Cancer Drug Targets

Research Background

Programmed death-1 ligand-1 (PD-L1, CD274, B7-H1) has been identified as the ligand for the immunoinhibitory receptor programmed death-1(PD1/PDCD1) and has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. PD-L1/B7-H1 is a member of the growing B7 family of immune molecules and this protein contains one V-like and one C-like Ig domain within the extracellular domain, and together with PD-L2, are two ligands for PD1 which belongs to the CD28/CTLA4 family expressed on activated lymphoid cells. By binding to PD1 on activated T-cells and B-cells, PD-L1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression. Accordingly, it leads to growth of immunogenic tumor growth by increasing apoptosis of antigen specific T cells and may contribute to immune evasion by cancers. PD-L1 thus is regarded as promising therapeutic target for human autoimmune disease and malignant cancers.Cancer ImmunotherapyCo-inhibitory Immune Checkpoint TargetsImmune CheckpointImmune Checkpoint Blockade: Blocking AntibodiImmune Checkpoint Blockade: PD-L1 / B7-H1 / CImmune Checkpoint Detection: AntibodiesImmune Checkpoint Detection: ELISA AntibodiesImmune Checkpoint Detection: FCM AntibodiesImmune Checkpoint Detection: ICC AntibodiesImmune Checkpoint Detection: IHC AntibodiesImmune Checkpoint Detection: WB AntibodiesImmune Checkpoint ProteinsImmune Checkpoint TargetsImmunotherapyPD-L1 / B7-H1 / CD274 Immune Checkpoint ProteTargeted Therapy

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481